Returning guest, Dr. Gregg Sylvester, MD, Chief Medical Officer at Seqirus, one of the world’s largest influenza vaccine providers discusses some new real-world evidence that was presented at the global International Society for Influenza and other Respiratory Virus Diseases (ISIRV) – World Health Organization (WHO) Virtual Conference that showed that cell-based quadrivalent seasonal influenza (QIVc) vaccines were more effective in children and adults and adjuvanted trivalent seasonal influenza vaccines (aTIV) were more effective in older populations.
Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer’s pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck’s HPV vaccine and Cabinet Secretary for Delaware’s Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.